Open Access. Powered by Scholars. Published by Universities.®
- Institution
-
- University of New Mexico (7)
- Boston University School of Law (2)
- Seattle University School of Law (2)
- University of Michigan Law School (2)
- University of Missouri School of Law (2)
-
- University of New Hampshire (2)
- University of Pittsburgh School of Law (2)
- University of Richmond (2)
- American University Washington College of Law (1)
- Cleveland State University (1)
- Florida State University College of Law (1)
- Georgetown University Law Center (1)
- Louisiana State University Law Center (1)
- Montclair State University (1)
- New York Law School (1)
- Pace University (1)
- The Peter A. Allard School of Law (1)
- The University of Akron (1)
- University of Georgia School of Law (1)
- University of Maryland Francis King Carey School of Law (1)
- University of Massachusetts Boston (1)
- Valparaiso University (1)
- Western New England University (1)
- Keyword
-
- FDA (8)
- FDCA (3)
- Food and Drug Administration (3)
- Regulation (3)
- Tobacco (3)
-
- Administrative law (2)
- Drugs (2)
- E-cigarettes (2)
- Medical research (2)
- Pharmaceutical (2)
- Pharmaceuticals (2)
- Utton Center (2)
- 17500 (1)
- 2014 (1)
- 23andMe (1)
- Advertising (1)
- Agricultural legislation (1)
- Amino acids (1)
- And Cosmetic Act (1)
- Antitrust (1)
- Athletes (1)
- Bioethics and the law (1)
- Biotech (1)
- Bob Jones University v. Commissioner (1)
- Botanical extracts (1)
- Capstone (1)
- Charitable organization (1)
- Charitable trust (1)
- Clinical data (1)
- Clinical trial regulation (1)
- Publication
-
- Publications (7)
- Articles (4)
- Faculty Scholarship (3)
- Faculty Articles (2)
- Faculty Publications (2)
-
- Law Faculty Scholarship (2)
- Law Student Publications (2)
- Akron Law Faculty Publications (1)
- Articles in Law Reviews & Other Academic Journals (1)
- Department of Nutrition and Food Studies Scholarship and Creative Works (1)
- Elisabeth Haub School of Law Faculty Publications (1)
- Georgetown Law Faculty Publications and Other Works (1)
- Homeland Security Publications (1)
- Journal Articles (1)
- Law Faculty Articles and Essays (1)
- Law Faculty Publications (1)
- Other Publications (1)
- Public Affairs Capstones Collection (1)
- Scholarly Publications (1)
- Scholarly Works (1)
- Transnational Business Governance Interactions Working Papers (1)
Articles 31 - 36 of 36
Full-Text Articles in Law
A Response To Professor Leff’S Tax Planning 'Olive Branch' For Marijuana Dealers, Philip Hackney
A Response To Professor Leff’S Tax Planning 'Olive Branch' For Marijuana Dealers, Philip Hackney
Articles
Professor Benjamin Leff argues in a forthcoming article entitled Tax Planning for Marijuana Dealers that a tax-exempt social welfare organization described in Internal Revenue Code section 501(c)(4) may sell medical marijuana without putting its exempt status in jeopardy. He argues that (1) the “public policy” doctrine applicable to charitable organizations under section 501(c)(3) does not apply to social welfare organizations, and (2) a social welfare organization may consider “community” law and ignore federal law in considering whether its activity meets the idea of social welfare. I argue that Leff is wrong and that the public policy doctrine applicable to charitable …
When Truth Cannot Be Presumed: The Regulation Of Drug Promotion Under An Expanding First Amendment, Christopher Robertson
When Truth Cannot Be Presumed: The Regulation Of Drug Promotion Under An Expanding First Amendment, Christopher Robertson
Faculty Scholarship
The Food, Drug, and Cosmetic Act (FDCA) requires that, prior to marketing a drug, the manufacturer must prove that it is safe and effective for the manufacturer’s intended uses, as shown on the proposed label. Nonetheless, physicians may prescribe drugs for other “off-label” uses, and often do so. Still, manufacturers have not been allowed to promote the unproven uses in advertisements or sales pitches.
This regime is now precarious due to an onslaught of scholarly critiques, a series of Supreme Court decisions that enlarge the First Amendment, and a landmark court of appeals decision holding that the First Amendment precludes …
The Presumption Against Expensive Health Care Consumption, Christopher Robertson
The Presumption Against Expensive Health Care Consumption, Christopher Robertson
Faculty Scholarship
This essay, as part of a symposium in honor of Professor Einer Elhauge, starts with his recognition that, for both epistemic and normative reasons, it remains profoundly difficult to regulate particular uses of medical technologies on the basis of their cost-benefit ratios. Nonetheless, this essay argues in favor of a general regulatory presumption against consumption for the most expensive medical technology usages, which drive most of aggregate healthcare spending. This essay synthesizes twelve facts about the ways in which medical technologies are produced, regulated, studied, and consumed to suggest that it is quite unlikely that the most expensive usages of …
23andme, The Food And Drug Administration, And The Future Of Genetic Testing, Patricia Zettler, Jacob S. Sherkow, Henry Greely
23andme, The Food And Drug Administration, And The Future Of Genetic Testing, Patricia Zettler, Jacob S. Sherkow, Henry Greely
Other Publications
On November 22, 2013, the US Food and Drug Administration (FDA) effectively halted health-related direct-to-consumer genetic testing in the United States by sending a warning letter to 23andMe, the leading company in the field, directing it to stop providing such testing. The FDA acted as the era of widespread, clinical use of DNA sequencing rapidly approaches. The agency’s action will contribute to changes in which genetic tests are offered to patients and how testing is provided.
A System Of Men And Not Of Laws: What Due Process Tells Us About The Deficiencies In Institutional Review Boards, Greer Donley
A System Of Men And Not Of Laws: What Due Process Tells Us About The Deficiencies In Institutional Review Boards, Greer Donley
Articles
Governmental regulation of human subjects research involves unique agency action. It delegates power to non-expert committees, Institutional Review Boards, to decide whether research protocols are "ethical" according to vague federal regulations. Without IRB approval, the protocol cannot be investigated. The empirical evidence regarding this system demonstrates that IRBs render deeply inconsistent and inaccurate outcomes. This Article argues that the lack of due process in the IRB system is to blame for such arbitrary agency action. By juxtaposing the levels of process required for IRB approval or research with FDA new drug approval--agency action involving similar interests--this Article highlights that IRBs …
The Inclusion Of Pregnant Women In Clinical Research, Barbara A. Noah
The Inclusion Of Pregnant Women In Clinical Research, Barbara A. Noah
Faculty Scholarship
In the past three decades, there has been unprecedented growth in medical research utilizing human subjects, with much promise for new treatments that extend life, improve quality of life, and prevent disease and disability. Safe prescribing of drug therapies requires that researchers design clinical trials to test products for the benefit of all persons who are likely to utilize them, not just a limited population. For this reason, it is essential that clinical trials include women, pregnant women, children, and racial minorities, as appropriate, because these populations sometimes exhibit different patterns of response or adverse reactions.
Despite some significant progress …